Form 4: National Healthcare Corp Director W. Andrew Adams Reports Option Grant

Director W. Andrew Adams reports the grant of stock options in National Healthcare Corp.

Summary

• W. Andrew Adams, a director of National Healthcare Corp (NHC), reported a transaction involving derivative securities.
• On May 9, 2024, Adams was granted options to purchase 7,500 shares of NHC common stock at an exercise price of $96.03 per share.
• These options were granted pursuant to the 2020 Omnibus Equity Incentive Plan and become exercisable on May 9, 2025, expiring on May 8, 2029.
• Adams also directly owns options from previous grants: 7,500 shares from the 2020 grant at $64.64, 7,500 shares from the 2021 grant at $71.64, 7,500 shares from the 2022 grant at $69.19, and 7,500 shares from the 2023 grant at $55.75.
• Additionally, Adams has direct and indirect ownership of common stock through various trusts and foundations.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of an option grant, which is neither particularly positive nor negative. It's a standard part of executive compensation.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders, incentivizing him to work towards increasing the company's stock value.

Industry Context

Stock option grants are a common practice in the healthcare industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages across the healthcare industry.
• Comparing the size and terms of this grant to those of similar companies like Brookdale Senior Living or Life Care Centers of America would provide a benchmark for its relative value.
• The vesting schedule and exercise price are typical for such grants.

Stakeholder Impact

• The option grant could potentially benefit shareholders if the director's performance leads to an increase in the company's stock price.

Key Dates